{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu X"],"funding":["Hangzhou Health Science and Technology Plan","Key project joint construction by Science and Technology Department of National Administration of TCM and Zhejiang Administration of TCM"],"pagination":["138"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12063397"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background
Varicella-zoster virus (VZV), a member of the α-herpesvirus family, is known for causing two distinct diseases: chickenpox (varicella) during the primary infection and shingles (zoster) due to reactivation of the virus later in life. Although there are vaccines available to prevent VZV infection, it is still not universally effective, and antiviral treatments for VZV are limited and may come with significant side effects. Thus, development of novel therapeutics is urgently needed.Methods
We identified a naturally occurring Alantolactone (ALT) that inhibited replication of recombinant VZV in human diploid fibroblast (WI-38 cells) and Adult Retinal Pigment Epithelial cell line-19 (ARPE-19 cells) through Western blotting, qPCR and plaque assays. Subsequently, we exp"],"journal":["Virology journal"],"pubmed_title":["Inhibitory effect of Alantolactone against varicella-zoster virus in vitro."],"pmcid":["PMC12063397"],"funding_grant_id":["A20220018","GZY-ZJ-KJ-24055","ZD2022005","GZY-ZJ-KJ-23088"],"pubmed_authors":["Lin P","Pan D","Wang S","Mao G","Kong C","Ding Z","Chang Y","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Inhibitory effect of Alantolactone against varicella-zoster virus in vitro.","description":"Background
Varicella-zoster virus (VZV), a member of the α-herpesvirus family, is known for causing two distinct diseases: chickenpox (varicella) during the primary infection and shingles (zoster) due to reactivation of the virus later in life. Although there are vaccines available to prevent VZV infection, it is still not universally effective, and antiviral treatments for VZV are limited and may come with significant side effects. Thus, development of novel therapeutics is urgently needed.Methods
We identified a naturally occurring Alantolactone (ALT) that inhibited replication of recombinant VZV in human diploid fibroblast (WI-38 cells) and Adult Retinal Pigment Epithelial cell line-19 (ARPE-19 cells) through Western blotting, qPCR and plaque assays. Subsequently, we exp","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T13:09:52.207Z","creation":"2026-04-18T03:11:23.293Z"},"accession":"S-EPMC12063397","cross_references":{"pubmed":["40346667"],"doi":["10.1186/s12985-025-02759-x"]}}